subject: The Clinical Observation On Docetaxel And Epirubicin In The Treatment Of Advanced Breast Cancer [print this page] Breast cancer is the most common malignancy in women. Its incidence is increasing year by year. Chemotherapy plays an important role in the comprehensive treatment of advanced breast cancer. It is important to select the ideal chemotherapy. Docetaxel and epirubicin are the most effective breast cancer treatment drugs and are widely used in chemotherapy of breast cancer. Research applications show that docetaxel and epirubicin can treat patients with advanced breast cancer. Its efficacy and safety are observed and tested.
View breast cancer as a systemic disease is increasingly being accepted by the people. The importance of chemotherapy in the treatment of breast cancer has been widely recognized. Docetaxel is a new generation of semisynthetic anticancer drugs, the department of its mechanism of action by acting on microtubules or tubulin system, promotes microtubule dimer assembly into microtubules and prevents to go poly process, which microtubule stabilization, block cells in G2 and M phase, and inhibit cancer cell proliferation and mitosis. Docetaxel than paclitaxel concentration in the cell three times, and a long residence time within the cell. In vivo, the mouse colon, breast, lung, ovarian tumor xenografts; cisplatin, etoposide, fluorouracil, paclitaxel resistant cell line, does not produce cross-resistance. The results of clinical trials show that docetaxel-based adjuvant chemotherapy for early breast cancer can improve the long-term survival and reduce the risk of recurrence. Epirubicin and doxorubicin compared with significantly lower bone marrow toxicity on the heart, high anti-tumor activity, its a simple 42% effective rate of breast cancer chemotherapy. Table of doxorubicin and docetaxel combination therapy in advanced breast cancer showed lower toxic effects on the blood system.
Pharmaceutical raw materials suppliers studies have shown that in multi docetaxel epirubicin treatment on advanced breast cancer, its CR rate is 7.14% and PR rate is 48.21%. The total efficiency is about 55.36%, it is higher than the reported treatment efficiency which simply using epirubicin. It shows that such joint programs can significantly improve advanced breast cancer clinical efficacy, for the treatment of advanced breast cancer. In addition, the main toxic effects of combination chemotherapy regimens for the gastrointestinal tract and bone marrow suppression, its incidence is slightly lower than the incidence reported in the literature in general was mild, Of course, this does not rule out the dose factors.
In summary, docetaxel combining with epirubicin is a good program for the treatment of advanced breast cancer. Especially for the retreatment patients, it has similar treatment efficiency with untreated patients, while its toxicity is resistant and does not affect chemotherapy. Therefore, the preliminary view that docetaxel combining with epirubicin is an effective treatment for advanced breast cancer. Of course, due to less research into the group of patients, effect of the two drug combination treatment for advanced breast cancer needs further clinical observation.
